ObjectiveTo investigate the effect of Amikacin combined with tegacycline on patients with drug-resistant Acinetobacter baumannii associated pneumonia of ICU and its effect on serum procalcitonin (PCT), interleukin-6 (IL-6) and C reactive protein (CRP) levels. Methods84 cases of drug-resistant Acinetobacter baumannii associated pneumonia of ICU treated in our hospital from June 2014 to October 2016 were divided into two groups according to random number table, 42 in each group. On the basis of routine treatment, the control group was treated with cefoperazone/sulbactam sodium for antibiotic treatment, the observation group were added with amikacin and tigecycline treatment on the basis of the control group treatment, the therapy lasted for 1 weeks. The changes of serum PCT, IL-6 and CRP levels and the incidence of adverse reactions were compared between the two groups after treatment. ResultsThe rate of bacterial clearance was 90.5% in the observation group and 64.3% in the control group. The bacterial clearance of the patients in the observation group was better than that of the control group, and the difference was statistically significant (P＜0.05). After the treatment, the serum levels of PCT, IL-6 and CRP in the two groups were lower than those in the control group, and the difference was statistically significant (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionAmikacin combined with tegacycline on patients with drug-resistant Acinetobacter baumannii associated pneumonia of ICU is safe and effective, which can significantly improve the clearance rate of bacteria and reduce the level of serum inflammatory factors.

无